Quintiles Transnational Holdings Inc  

(Public, NYSE:Q)   Watch this stock  
Find more results for BIO CLINICAL DEVELOPMENT, INC.�
75.45
+1.37 (1.85%)
After Hours: 75.45 0.00 (0.00%)
Jul 26, 4:23PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 73.68 - 75.80
52 week 55.01 - 80.45
Open 74.23
Vol / Avg. 0.00/1.28M
Mkt cap 9.04B
P/E 22.96
Div/yield     -
EPS 3.29
Shares 119.67M
Beta 0.47
Inst. own 89%
Jul 27, 2016
Q2 2016 Quintiles Transnational Holdings Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 27, 2016
Q2 2016 Quintiles Transnational Holdings Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 7, 2016
Quintiles Transnational Holdings Inc at Jefferies Healthcare Conference
May 6, 2016
Quintiles Transnational Holdings Inc Annual Shareholders Meeting (Estimated)
May 5, 2016
Quintiles Transnational Holdings Inc Annual Shareholders Meeting
May 3, 2016
Q1 2016 Quintiles Transnational Holdings Inc Earnings Release
May 3, 2016
Q1 2016 Quintiles Transnational Holdings Inc Earnings Call
May 3, 2016
IMS Health Holdings Inc and Quintiles Transnational Holdings Inc to Merge- M&A Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 7.14% 6.62%
Operating margin 12.00% 11.13%
EBITD margin - 14.08%
Return on average assets 10.79% 10.52%
Return on average equity - -
Employees 36,100 -
CDP Score - 94 D

Address

4820 Emperor Blvd
DURHAM, NC 27703-8426
United States - Map
+1-919-9982000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Quintiles Transnational Holdings Inc. is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. The Company's segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Product Development segment consists of clinical solutions and services, and advisory services. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

Officers and directors

Jack M. Greenberg CPA Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Thomas H. Pike Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Michael R. McDonnell Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Kevin K. Gordon Chief Operating Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
James H. Erlinger III Executive Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Dennis B. Gillings CBE Ph.D. Director
Age: 71
Bio & Compensation  - Reuters
John P. Connaughton Independent Director
Age: 50
Bio & Compensation  - Reuters
Jonathan J. Coslet Independent Director
Age: 51
Bio & Compensation  - Reuters
Michael J. Evanisko Independent Director
Age: 66
Bio & Compensation  - Reuters
John M. Leonard M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters